Clinical Trials List
2020-07-31 - 2021-12-07
Phase II
Recruiting5
ICD-10J21.0
Acute bronchiolitis due to respiratory syncytial virus
ICD-9466.11
Acute bronchiolitis due to respiratory syncytial virus(RSV)
Randomized, double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of RV521 in the treatment of adult subjects who have undergone hematopoietic cell transplantation (HCT) with a documented upper respiratory tract infection (URTI) with respiratory syncytial virus (RSV).
-
Trial Applicant
Syneos Health
-
Sponsor
ReViral Ltd
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ming-Yu Lien Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- Ming-Hung Tsai Division of Hematology & Oncology
- Tzu-Ting Chen Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Chen-Yuan Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Hao-Yuan Wang Division of Hematology & Oncology
- Chia-Jen Liu Division of Hematology & Oncology
- Jyh-Pyng Gau Division of Hematology & Oncology
- Po-Shen Ko Division of Hematology & Oncology
- Ting-An Lin Division of Hematology & Oncology
- Liang-Tsai Hsiao Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Shih-Feng Cho Division of Hematology & Oncology
- Jeng-Shiun Du Division of Hematology & Oncology
- Yi-Chang Liu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
13 participants
-
Global
200 participants
